التفاصيل البيبلوغرافية
| العنوان: |
Cancer Precision-Prevention trial of Metformin in adults with Li Fraumeni syndrome (MILI) undergoing yearly MRI surveillance: a randomised controlled trial protocol. |
| المؤلفون: |
Dixon-Zegeye, Miriam1 (AUTHOR), Shaw, Rachel2 (AUTHOR), Collins, Linda2 (AUTHOR), Perez-Smith, Kendra3 (AUTHOR), Ooms, Alexander4 (AUTHOR), Qiao, Maggie4 (AUTHOR), Pantziarka, Pan5 (AUTHOR), Izatt, Louise6 (AUTHOR), Tischkowitz, Marc7 (AUTHOR), Harrison, Rachel E.8 (AUTHOR), George, Angela9 (AUTHOR), Woodward, Emma R.10,11 (AUTHOR), Lord, Simon1 (AUTHOR), Hawkes, Lara12 (AUTHOR), Evans, D. Gareth10,11 (AUTHOR), Franklin, James13 (AUTHOR), Hanson, Helen14,15 (AUTHOR), Blagden, Sarah P.1,2 (AUTHOR) sarah.blagden@oncology.ox.ac.uk |
| المصدر: |
Trials. 2/2/2024, Vol. 25 Issue 1, p1-14. 14p. |
| مصطلحات موضوعية: |
*LI-Fraumeni syndrome, *RANDOMIZED controlled trials, *TUMOR markers, *METFORMIN, *MAGNETIC resonance imaging, *VOXEL-based morphometry, *ANTINEOPLASTIC agents |
| مستخلص: |
Background: Li-Fraumeni syndrome (LFS) is a rare autosomal dominant disease caused by inherited or de novo germline pathogenic variants in TP53. Individuals with LFS have a 70–100% lifetime risk of developing cancer. The current standard of care involves annual surveillance with whole-body and brain MRI (WB-MRI) and clinical review; however, there are no chemoprevention agents licensed for individuals with LFS. Preclinical studies in LFS murine models show that the anti-diabetic drug metformin is chemopreventive and, in a pilot intervention trial, short-term use of metformin was well-tolerated in adults with LFS. However, metformin's mechanism of anticancer activity in this context is unclear. Methods: Metformin in adults with Li-Fraumeni syndrome (MILI) is a Precision-Prevention phase II open-labelled unblinded randomised clinical trial in which 224 adults aged ≥ 16 years with LFS are randomised 1:1 to oral metformin (up to 2 mg daily) plus annual MRI surveillance or annual MRI surveillance alone for up to 5 years. The primary endpoint is to compare cumulative cancer-free survival up to 5 years (60 months) from randomisation between the intervention (metformin) and control (no metformin) arms. Secondary endpoints include a comparison of cumulative tumour-free survival at 5 years, overall survival at 5 years and clinical characteristics of emerging cancers between trial arms. Safety, toxicity and acceptability of metformin; impact of metformin on quality of life; and impact of baseline lifestyle risk factors on cancer incidence will be assessed. Exploratory end-points will evaluate the mechanism of action of metformin as a cancer preventative, identify biomarkers of response or carcinogenesis and assess WB-MRI performance as a diagnostic tool for detecting cancers in participants with LFS by assessing yield and diagnostic accuracy of WB-MRI. Discussion: Alongside a parallel MILI study being conducted by collaborators at the National Cancer Institute (NCI), MILI is the first prevention trial to be conducted in this high-risk group. The MILI study provides a unique opportunity to evaluate the efficacy of metformin as a chemopreventive alongside exploring its mechanism of anticancer action and the biological process of mutated P53-driven tumourigenesis. Trial registration: ISRCTN16699730. Registered on 28 November 2022. URL: https://www.isrctn.comTest/ EudraCT/CTIS number 2022-000165-41. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder